<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111144">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146365</url>
  </required_header>
  <id_info>
    <org_study_id>VAC-011</org_study_id>
    <nct_id>NCT02146365</nct_id>
  </id_info>
  <brief_title>Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers</brief_title>
  <official_title>Prospective Study to Assess the Nasopharyngeal Carriage of SPn, Long Term Safety and Immune Persistence in Healthy Kenyan PCV-primed Toddlers Who Received PATH-wSP Compared to Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <authority>Kenya: Ethical Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One possible mechanism of protection from pneumococcal disease with a killed whole cell
      vaccine is  by altering the carriage of pneumococcus germs in the nose and throat of those
      who get the vaccine.  This study will look at nasal swabs from toddlers who received a
      killed whole cell pneumococcal vaccine (PATH-wSP) in VAC-010 and compare them to nasal swabs
      from toddlers of the same age who did not receive the PATH-wSP vaccine. This information
      will be used to help further develop the PATH-wSP vaccine. The research will be done in
      Kenya at one site in Kisumu (KEMRI). The study will enroll healthy Kenyan toddlers (12-15
      months of age) who are participating in the VAC-010 study (N=250) and whose parents provide
      consent for this study. In addition 50 healthy Kenyan toddlers of similar age who did not
      participate in the VAC-010 study will also be enrolled.

      The toddlers will be followed for 6 months and will have 5 study visits. During those study
      visits each toddler will have their nose and back of their throat swabbed. The material from
      the swab will be analyzed for the presence and type of pneumococcal and other germs. At the
      last visit, one blood sample (5 ml or approximately 1 tsp) will be obtained.

      There will be no direct benefit to the participants other than direct and immediate medical
      care as needed.

      Parents of all participants will provide written informed consent.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Prevalence of SPn in nasopharynx</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of Streptococcus pneumoniae (SPn) detected by quantitative PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of SPn in nasopharynx</measure>
    <time_frame>4 weeks after final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of Streptococcus pneumoniae (SPn) detected by quantitative PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of SPn in nasopharynx</measure>
    <time_frame>8 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of Streptococcus pneumoniae (SPn) detected by quantitative PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of SPn in nasopharynx</measure>
    <time_frame>12 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of Streptococcus pneumoniae (SPn) detected by quantitative PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of SPn in nasopharynx</measure>
    <time_frame>24 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of Streptococcus pneumoniae (SPn) detected by quantitative PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serotype specific SPn in nasopharynx</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of serotype specific Streptococcus pneumoniae (SPn) detected by micro array analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serotype specific SPn in nasopharynx</measure>
    <time_frame>4 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of serotype specific Streptococcus pneumoniae (SPn) detected by micro array analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serotype specific SPn in nasopharynx</measure>
    <time_frame>8 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of serotype specific Streptococcus pneumoniae (SPn) detected by micro array analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serotype specific SPn in nasopharynx</measure>
    <time_frame>12 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of serotype specific Streptococcus pneumoniae (SPn) detected by micro array analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of serotype specific SPn in nasopharynx</measure>
    <time_frame>24 weeks post final vaccination in VAC-010</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of serotype specific Streptococcus pneumoniae (SPn) detected by micro array analysis</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>PATH-wSP 300 + Booster</arm_group_label>
    <description>2 doses of PATH-wSP 300 mcg + Pentavac PFS Booster + Synflorix (3 separate injections) 8 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 600 + Booster</arm_group_label>
    <description>2 doses of PATH-wSP 600 mcg + Pentavac PFS booster + Synflorix (3 separate injections) 8 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 300</arm_group_label>
    <description>2 doses of PATH-wSP 300 mcg + 2 injections of saline  (3 separate injections) 8 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATH-wSP 600</arm_group_label>
    <description>2 doses of PATH-wSP 600 mcg + 2 injections of saline  (3 separate injections) 8 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Booster control</arm_group_label>
    <description>1 dose of Pentavac PFS booster + 1 injection Synflorix and 1 injection of saline  (3 separate injections) followed 8 weeks later by 3 injections of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV primed only</arm_group_label>
    <description>a group of toddlers who were not included in the VAC-010 study and who have not received either Pentavac PFS boost or Synflorix.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nasopharyngeal swab</intervention_name>
    <arm_group_label>PATH-wSP 300 + Booster</arm_group_label>
    <arm_group_label>PATH-wSP 600 + Booster</arm_group_label>
    <arm_group_label>PATH-wSP 300</arm_group_label>
    <arm_group_label>PATH-wSP 600</arm_group_label>
    <arm_group_label>Booster control</arm_group_label>
    <arm_group_label>PCV primed only</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy PCV- primed Kenyan toddlers; some of whom have participated in VAC-010 (n=250) and
        some of whom have not (n=50)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Toddlers Enrolled in VAC-010:

               -  Randomization in VAC-010.

               -  Subject's parent must provide voluntary written informed consent for subject to
                  participate in the study, is fully capable of comprehending and complying with
                  study requirements and procedures, able and willing to return for all scheduled
                  follow-up visits, and has expressed availability for the required study period,
                  with access to a consistent means of telephone contact. An illiterate parent
                  will require an impartial witness to be present during consenting process to
                  include discussing the consent form, verbal consent and thumb-printing.

               -  Subject has not completed his or her final vaccination in VAC-010.

        For Toddlers NOT Enrolled in VAC-010 (PCV-primed-only cohort):

          -  Healthy Kenyan toddlers between 12 to 15 (inclusive) months of age who have completed
             their primary EPI vaccines, with the exception that the birth dose of oral polio
             vaccine is not required. See Appendix A for a summary of the Kenyan EPI schedule.

          -  Subjects who have not received a PCV booster following primary PCV series.

          -  Subject's parent must provide voluntary written informed consent for subject to
             participate in the study, is fully capable of comprehending and complying with study
             requirements and procedures, able and willing to return for all scheduled follow-up
             visits, and has expressed availability for the required study period, with access to
             a consistent means of telephone contact. An illiterate parent will require an
             impartial witness to be present during consenting process to include discussing the
             consent form, verbal consent and thumb-printing.

          -  Subjects who were not born premature, had a birth weight of &gt; 2.5 kg, and who have a
             weight-to-height Z score of â‰¥ -2 at the time of enrollment.

        Exclusion Criteria:

          -  For Toddlers NOT enrolled in VAC-010 (PCV-primed only):

               -  Use of any investigational or nonregistered drug within 90 days prior to
                  screening, or planned during the course of study participation.

               -  Immunosuppression or immunodeficiency (inclusive of human immunodeficiency virus
                  [HIV]) by medical history (inclusive of possible HIV through maternal fetal
                  transfer at time of birth or through breast milk).

               -  Chronic, clinically significant pulmonary, cardiovascular, hepatobiliary,
                  gastrointestinal, renal, neurological, or hematological functional abnormality
                  or major congenital defects or illness that requires medical therapy, by medical
                  history or clinical assessment. This includes abnormal vital signs as assessed
                  by toxicity scoring (Appendix B).

               -  Any medical or social condition that in the opinion of the investigator may
                  interfere with the study objectives, pose a risk to the study subject, or
                  prevent the subject from completing the study.

               -  An employee (or first degree relative of employee) of the Sponsor, the Clinical
                  Research Organization (CRO), the investigator or any site personnel.

               -  Disorders that require (d) chronic administration (defined as more than 14
                  consecutive days) of immunosuppressants or other immune-modifying drugs within
                  the 6 months prior to enrollment. An immunosuppressant dose of glucocorticoid
                  will be defined as a systemic dose &gt;10 mg of prednisone (adult dosage) adjusted
                  for equivalent dosing in toddlers by weight. The use of topical glucocorticoids
                  will be permitted.

               -  Administration of immunoglobulins and/or any blood products within the 6 months
                  preceding enrollment in the study; or anticipation of such administration during
                  the study period.

               -  History of meningitis, seizures or any neurological disorder.

               -  Subject who has evidence of congenital abnormality or developmental delay.

               -  Any evidence of fetal alcohol syndrome or history of alcohol abuse in mother
                  during pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nekoye Otsyula, MB ChB MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute/Walter Reed Project</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nekoye N Otsyula, MB, ChB, MSc</last_name>
    <phone>+254 714 481 488</phone>
    <email>Nekoye.Otsyula@usamru-k.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kenya Medical Research Institute/Walter Reed Project</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nekoye Otsyula, MB,ChB, MSc</last_name>
      <phone>+254 7222 239 828</phone>
      <email>Nekoye.Otsyula@usamru-k.org</email>
    </contact>
    <investigator>
      <last_name>Nekoye Otsyula, MB ChB MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
